Recursion Pharmaceuticals
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Recursion Pharmaceuticals's past years’ income statements indicate that its last revenue has increased compared to the previous period by 12% to $44,575,000. Profit margin reached -736%. Total operating expenses were $352,048,000.
Profit Margin
| 2019 | 1.71M | -62.52M | -3654.3% |
|---|---|---|---|
| 2020 | 3.41M | -87.88M | -2574.92% |
| 2021 | 10M | -178.07M | -1780.74% |
| 2022 | 39.68M | -239.42M | -603.36% |
| 2023 | 44.57M | -328.06M | -735.99% |
RXRX Income Statement (2019 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
Revenue | |||||
Revenue | 44.57M | 39.68M | 10M | 3.41M | 1.71M |
Cost of revenue | 42.58M | 48.27M | 9.10M | 63.31M | 45.80M |
Gross profit | 1.98M | -8.59M | 896K | -59.90M | -44.09M |
Operating exp. | |||||
Research and development | 241.22M | 155.69M | 135.27M | 63.31M | 45.80M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 352.04M | 237.13M | 192.77M | 88.02M | 64.15M |
Operating income | -350.06M | -245.72M | -182.77M | -84.61M | -62.44M |
Other income (expenses), net | 17.93M | 6.25M | -3.70M | -2.39M | 562K |
Income before tax | -332.12M | -239.47M | -186.47M | -87.00M | -61.87M |
Income tax expense | -4.06M | -55K | -8.40M | 876K | 646K |
Net income | -328.06M | -239.42M | -178.07M | -87.88M | -62.52M |
Earnings per share | |||||
Basic EPS | -1.58 | -1.36 | -1.05 | -0.52 | -0.38 |
Diluted EPS | -1.58 | -1.36 | -1.05 | -0.52 | -0.38 |
| Data source | Data source | Data source |